금연 문제 인간 면역 결핍 바이러스 하이브리드 시험 (QMH)
HIV와 함께 사는 사람의 금연을위한 디지털 치료의 하이브리드 시험
The purpose of this study is to compare the advantages and disadvantages of two approaches for quitting smoking among people living with HIV (PWH). Participants will complete a 24- week (~6-month) study where the Participants will be assigned to one of two smartphone apps to help with quitting smoking. Regardless of the group participants are assigned to, they will also receive a combination of nicotine replacement therapy (patches and gums) that have been shown to help people quit smoking. The main questions this study aims to answer are:
Participants will complete 6 video call visits over about 6 months. Participants will install their assigned smoking cessation app onto their phone and will be asked to use the app for the duration of the study along with their provided Nicotine Replacement Therapy (NRT) products. During the study visits, participants will meet with study staff to complete questionnaires and interviews. Participants may be asked to provide breath and saliva samples to measure the level of carbon monoxide and nicotine.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
Tobacco use has alarmingly high rates among people with Human Immunodeficiency Virus (HIV) (PWH), 43% compared with 15% in the general population. Due to the development of highly effective treatments for HIV and the resulting increased longevity among PWH, this population now loses more life years to smoking than to HIV infection itself. Novel and effective models to deliver wider reaching smoking cessation interventions for PWH are highly needed and indicated as a priority for National Institute of Health. Digital therapeutics (DTx) may be a novel, scalable, and highly available approach for engaging and treating smoking in this population. However, although DTx for smoking cessation have been shown effective in the general population, no large trial to date has examined the effectiveness of a tailored DTx for smoking cessation in PWH, and no implementation science work has examined barriers and facilitators of implementation of DTx for smoking cessation in this population.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 해당 없음
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Clinical Studies Coordinator
- 전화번호: (984) 377-4306
- 이메일: caitlyn.arnold@advocatehealth.org
연구 연락처 백업
- 이름: Roger Vilardaga Vierra, Ph.D.
- 전화번호: 336-716-1495
- 이메일: Roger.Vilardaga@wfusm.edu
연구 장소
-
-
North Carolina
-
Winston-Salem, North Carolina, 미국, 27101
- 모병
- Wake Forest University, Implementation Science
-
연락하다:
- Principal Investigator
- 전화번호: 919-439-3498
- 이메일: Roger.Vilardagaviera@advocatehealth.org
-
연락하다:
- Clinical Studies Coordinator
- 전화번호: (984)377-4306
- 이메일: caitlyn.arnold@advocatehealth.org
-
수석 연구원:
- Roger Vilardaga
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Self-reported daily cigarette smoking over the past 30 days
- Self-reported HIV status
- Age 18 or older
- Desire to quit smoking
- Willing and medically eligible to use NRT
- Currently receiving HIV care
- Currently owning an Android or iOS smartphone
Exclusion Criteria:
- Current acute psychotic episode or unsafe to participate in the study
- Pregnant or intending to become pregnant in the next 6 months
- Currently receiving any pharmacological and/or behavioral intervention or counseling for smoking cessation
- Any medical condition or medication that could compromise subject safety, as determined by the PIs and/or study physician
- Not able to fluently speak and write in English
- Hearing, comprehension, visual, speech, or motor limitations that preclude study participation
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Learn to Quit - HIV (LTQ-H) App
a smoking cessation Digital Therapeutic (DTx) for people with HIV (PWH) |
LTQ-H consists of 319 screens divided into: (a) HIV-tailored smoking cessation ACT skills, (b) education about tobacco dependence and treatment (USCPG), and (c) NRT psychoeducation and adherence. Content is gradually presented across 28 modules (14 education and 14 skills) that can be completed in 14 days.
다른 이름들:
|
|
활성 비교기: QuitStart App
an evidence-based DTx designed for the general population |
This DTx, QuitGuide was adapted from the National Cancer Institute Smokefree.gov Initiative's QuitGuide's 5 modules have the following intervention components: (a) psychoeducation about the impact of smoking on health, (b) setting up a quit date and a quit plan, (c) selecting reasons for quitting, (d) tracking triggers and smoking habits, and (e) tips for quitting.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Biochemically verified 7-day point prevalence abstinence at 6, 12, 18, and 24-weeks
기간: Weeks 6, 12, 18, and 24
|
Abstinence is determined by a self-report of not smoking any cigarettes for greater than or equal to 7 days prior to Weeks 6, 12, 18, and 24 and biochemically verified by an expired carbon monoxide breath test or a cotinine level saliva test at Weeks 6, 12, 18, and 24. Criteria for the bioverification tests to be considered abstinent includes a reading of <6 parts per million using an iCOquit Smokerlyzer carbon monoxide breath test OR a cotinine level of 30 or less ng/ml using an iScreen saliva test. If the participant does not meet both criteria of the self report of 7 or more days of abstinence plus a bioverification test below the thresholds listed above, they are not considered abstinent. As per convention, participants are assumed to be smoking if they report smoking at the time-point, cannot be reached to provide data at the time-point, fail to provide a breath sample at the time-point, or provide a breath sample at the time-point that is greater than or equal to 6 ppm. |
Weeks 6, 12, 18, and 24
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Self-reported 7-day point prevalence abstinence at 6 weeks - the percentage of participants who are abstinent from cigarettes at a given point in time
기간: 6 weeks
|
Percent of subjects in each group self-reporting no smoking at all for greater or equal to 7 days prior to the timepoint. |
6 weeks
|
|
Self-reported 7-day point prevalence abstinence at 12 weeks - the percentage of participants who are abstinent from cigarettes at a given point in time
기간: 12 weeks
|
Percent of subjects in each group self-reporting no smoking at all for greater or equal to 7 days prior to the timepoint. |
12 weeks
|
|
Self-reported 7-day point prevalence abstinence at 18 weeks - the percentage of participants who are abstinent from cigarettes at a given point in time
기간: 18 weeks
|
Percent of subjects in each group self-reporting no smoking at all for greater or equal to 7 days prior to the timepoint. |
18 weeks
|
|
Self-reported 7-day point prevalence abstinence at 24 weeks - the percentage of participants who are abstinent from cigarettes at a given point in time
기간: 24 weeks
|
Percent of subjects in each group self-reporting no smoking at all for greater or equal to 7 days prior to the timepoint. |
24 weeks
|
|
Self-reported 30-day point prevalence abstinence at 6 weeks - the percentage of participants who are abstinent from cigarettes at a given point in time
기간: 6 weeks
|
Percent of subjects in each group self-reporting no smoking at all for greater or equal to 30 days but < 30 days prior to the timepoint. |
6 weeks
|
|
Self-reported 30-day point prevalence abstinence at 12 weeks - the percentage of participants who are abstinent from cigarettes at a given point in time
기간: 12 weeks
|
Percent of subjects in each group self-reporting no smoking at all for greater or equal to 30 days prior to the timepoint. |
12 weeks
|
|
Self-reported 30-day point prevalence abstinence at 18 weeks - the percentage of participants who are abstinent from cigarettes at a given point in time
기간: 18 weeks
|
Percent of subjects in each group self-reporting no smoking at all for greater or equal to 30 days prior to the timepoint. |
18 weeks
|
|
Self-reported 30-day point prevalence abstinence at 24 weeks - the percentage of participants who are abstinent from cigarettes at a given point in time
기간: 24 weeks
|
Percent of subjects in each group self-reporting no smoking at all for greater or equal to 30 days prior to the timepoint. |
24 weeks
|
|
Change in average number of cigarettes smoked per day
기간: 6 weeks
|
Change in self-reported number of cigarettes smoked per day, averaged within groups. |
6 weeks
|
|
Change in average number of cigarettes smoked per day
기간: 12 weeks
|
Change in self-reported number of cigarettes smoked per day, averaged within groups. |
12 weeks
|
|
Change in average number of cigarettes smoked per day
기간: 18 weeks
|
Change in self-reported number of cigarettes smoked per day, averaged within groups. |
18 weeks
|
|
Change in average number of cigarettes smoked per day
기간: 24 weeks
|
Change in self-reported number of cigarettes smoked per day, averaged within groups. |
24 weeks
|
|
Average number of quit attempts
기간: 6 weeks
|
Average number of quit attempts self-reported per group at the specified time point. Quit attempts are defined by no smoking cigarettes at all for 24 hours or more. |
6 weeks
|
|
Average number of quit attempts
기간: 12 weeks
|
Average number of quit attempts self-reported per group at the specified time point. Quit attempts are defined by no smoking cigarettes at all for 24 hours or more. |
12 weeks
|
|
Average number of quit attempts
기간: 18 weeks
|
Average number of quit attempts self-reported per group at the specified time point. Quit attempts are defined by no smoking cigarettes at all for 24 hours or more. |
18 weeks
|
|
Average number of quit attempts
기간: 24 weeks
|
Average number of quit attempts self-reported per group at the specified time point. Quit attempts are defined by no smoking cigarettes at all for 24 hours or more. |
24 weeks
|
|
Average acceptance of physical smoking cravings
기간: 6 weeks
|
Average self-reported scores of acceptance of cravings on the physical sensations subscale of the Avoidance and Inflexibility Scale. Scores range from 4-20 with lower scores indicating more acceptance of smoking cravings. |
6 weeks
|
|
Average acceptance of physical smoking cravings
기간: 12 weeks
|
Average self-reported scores of acceptance of cravings on the physical sensations subscale of the Avoidance and Inflexibility Scale. Scores range from 4-20 with lower scores indicating more acceptance of smoking cravings. |
12 weeks
|
|
Average acceptance of physical smoking cravings
기간: 18 weeks
|
Average self-reported scores of acceptance of cravings on the physical sensations subscale of the Avoidance and Inflexibility Scale. Scores range from 4-20 with lower scores indicating more acceptance of smoking cravings. |
18 weeks
|
|
Average acceptance of physical smoking cravings
기간: 24 weeks
|
Average self-reported scores of acceptance of cravings on the physical sensations subscale of the Avoidance and Inflexibility Scale. Scores range from 4-20 with lower scores indicating more acceptance of smoking cravings. |
24 weeks
|
|
Average frequency of app use
기간: Weeks 0-24
|
Average frequency of app use over the 24-week study period. Measured by average number of app openings. |
Weeks 0-24
|
|
Average duration of app use
기간: Weeks 0-24
|
Average duration of app use over the 24-week study period. |
Weeks 0-24
|
|
Average number of app modules completed
기간: Weeks 0-24
|
Average number of app modules completed over the 24-week study period. |
Weeks 0-24
|
공동 작업자 및 조사자
협력자
협력자
수사관
수사관
- 수석 연구원: Roger Vilardaga Viera, Ph.D., Wake Forest University Health Sciences
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- IRB00112958
- 7R01CA285331-02 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .